Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 6/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21192033 | 0.83 | OGA (0.33) | GPR119HRH3ACACBOGANAAA | |
| SCHEMBL719387 | 0.81 | PDE10A (0.35) | ACACBHCRTR1HCRTR2 | |
| SCHEMBL21192296 | 0.81 | GPR119 (0.37) | GPR119HRH3ACACBOGANAAA | |
| SCHEMBL719906 | 0.80 | CYP2D6 (0.46) | GPR119 | |
| SCHEMBL10052757 | 0.80 | ALDH1A1 (0.35) | GPR119HRH3ACACBHCRTR1HCRTR2 | |
| SCHEMBL21177913 | 0.80 | EPHX2 (0.35) | GPR119HRH3OGANAAA | |
| SCHEMBL21178117 | 0.80 | EPHX2 (0.35) | GPR119HRH3OGANAAA | |
| SCHEMBL16042062 | 0.80 | EPHX2 (0.35) | GPR119HRH3OGANAAA | |
| SCHEMBL717550 | 0.78 | SMYD3 (0.36) | GPR119ACACBHCRTR1HCRTR2 | |
| SCHEMBL1004837 | 0.77 | GPR119 (0.53) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | GPR119 1/4885HRH3 870/4885ACACB 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.